Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
Superinvestors holding CHRS, Q2 2026
No superinvestor reported holding CHRS in Q2 2026.